Cargando…

Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients

BACKGROUND: Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelttari, Liisa M, Nurminen, Riikka, Gylfe, Alexandra, Aaltonen, Lauri A, Schleutker, Johanna, Nevanlinna, Heli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522023/
https://www.ncbi.nlm.nih.gov/pubmed/23176254
http://dx.doi.org/10.1186/1471-2407-12-552
_version_ 1782253029196562432
author Pelttari, Liisa M
Nurminen, Riikka
Gylfe, Alexandra
Aaltonen, Lauri A
Schleutker, Johanna
Nevanlinna, Heli
author_facet Pelttari, Liisa M
Nurminen, Riikka
Gylfe, Alexandra
Aaltonen, Lauri A
Schleutker, Johanna
Nevanlinna, Heli
author_sort Pelttari, Liisa M
collection PubMed
description BACKGROUND: Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied. METHODS: To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR. RESULTS: No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer patients. CONCLUSIONS: The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.
format Online
Article
Text
id pubmed-3522023
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35220232012-12-14 Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients Pelttari, Liisa M Nurminen, Riikka Gylfe, Alexandra Aaltonen, Lauri A Schleutker, Johanna Nevanlinna, Heli BMC Cancer Research Article BACKGROUND: Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied. METHODS: To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR. RESULTS: No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer patients. CONCLUSIONS: The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer. BioMed Central 2012-11-23 /pmc/articles/PMC3522023/ /pubmed/23176254 http://dx.doi.org/10.1186/1471-2407-12-552 Text en Copyright ©2012 Pelttari et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pelttari, Liisa M
Nurminen, Riikka
Gylfe, Alexandra
Aaltonen, Lauri A
Schleutker, Johanna
Nevanlinna, Heli
Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
title Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
title_full Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
title_fullStr Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
title_full_unstemmed Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
title_short Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
title_sort screening of finnish rad51c founder mutations in prostate and colorectal cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522023/
https://www.ncbi.nlm.nih.gov/pubmed/23176254
http://dx.doi.org/10.1186/1471-2407-12-552
work_keys_str_mv AT pelttariliisam screeningoffinnishrad51cfoundermutationsinprostateandcolorectalcancerpatients
AT nurminenriikka screeningoffinnishrad51cfoundermutationsinprostateandcolorectalcancerpatients
AT gylfealexandra screeningoffinnishrad51cfoundermutationsinprostateandcolorectalcancerpatients
AT aaltonenlauria screeningoffinnishrad51cfoundermutationsinprostateandcolorectalcancerpatients
AT schleutkerjohanna screeningoffinnishrad51cfoundermutationsinprostateandcolorectalcancerpatients
AT nevanlinnaheli screeningoffinnishrad51cfoundermutationsinprostateandcolorectalcancerpatients